利利的糖尿病药物Foundayo符合心血管目标, Lilly's diabetes drug Foundayo meets cardiovascular goals for FDA approval.

伊利莉宣布,其针对2型糖尿病的Foundayo 3期试验表明在减少主要心血管不良事件方面与胰岛素格拉金无劣. Eli Lilly announced that its Phase 3 trial of Foundayo for type 2 diabetes demonstrated non-inferiority to insulin glargine in reducing major adverse cardiovascular events. 治疗也显示A1C水平和体重的改善,心血管死亡风险较低. The treatment also showed superior improvements in A1C levels and body weight, with a lower risk of cardiovascular death. 利利计划在2026年第二季度结束之前提交药物获得FDA批准. Lilly plans to submit the drug for FDA approval by the end of the second quarter of 2026.